Biomedical Alliance in Europe (BioMed Alliance) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have called for EU policymakers to work together to improve translational research outcomes, progressing scientific ideas through to clinical applications.
Currently translational research is costly and risky, as there are few funding activities, and fragmented, as there are no instruments to guide organisations through the complete medicine lifecycle.
BioMed Alliance and EFPIA propose that this situation could be radically improved by:
- ‘Increasing visibility on the role and needs of translational research to better inform policy-makers, academia, patients and the general public.
- Improving collaboration among all actors from the translational research value chain, including patients, scientists, clinicians, physicians, regulators, industry and addressing the current gaps in the innovation cycle by promoting a more effective use of existing and future funding tools to support translational research such as the Innovative Medicines Initiative (IMI 2) and the next public private partnership under Horizon Europe, respectively, while taking advice and recommendations on board from diverse stakeholders.
- Facilitating translational research strategic planning to optimise outcomes and enable progress is much needed under Horizon Europe. Science-led mechanisms should be established to build on synergies between health research programmes, break down the silo approaches in the innovation cycle and boost the visibility and effectiveness of European health research.’
For further information, please see EFPIA’s full press release here.